Pharmacology Research

KEY FINDING: NLX-112 treatment significantly improves locomotion in a dose-dependent fashion, suggesting a direct relationship between the amount of drug and the improvement in walking ability.

KEY FINDING: The researchers successfully developed and characterized five humanized anti-CD11d monoclonal antibodies.

KEY FINDING: The OPDL gel demonstrated excellent injectability and self-healing properties, allowing its precise application at the site of spinal cord injury by using a syringe for effective care delivery.

KEY FINDING: A total of 1,651 articles were identified, and publication numbers showed a consistent annual increase.

KEY FINDING: Updated guidelines suggest a broader MAP target range of 75–80 mmHg as the lower limit and 90–95 mmHg as the upper limit for 3–7 days of treatment post-SCI.

KEY FINDING: Zinc ions modulate inflammatory pathways through IKBα, which inhibits NF-κB activity, reducing inflammation and cell death in SCI mouse model.

KEY FINDING: Lipid nanovesicles, including liposomes and extracellular vesicles, can be modified to enhance their ability to target specific cells and tissues in the spinal cord.

KEY FINDING: Metformin significantly enhances locomotor function after SCI in rodent models. It also improves mechanical allodynia and thermal hyperalgesia, indicating pain alleviation.

KEY FINDING: Targeted blockade of spinal α2 adrenoceptors can reduce spinal nociceptive transmission in vivo.

KEY FINDING: TPTD significantly increased bone mineral density and other key bone indicators after SCI in rats, while ALN did not show significant improvement in these areas.